- (E/Z)-Zotiraciclib
-
- $38.00 / 1mg
-
2024-11-19
- CAS:937270-47-8
- Min. Order:
- Purity: 99.12%
- Supply Ability: 10g
|
| Product Name: | SB1317 | | Synonyms: | TG-02/SB-1317;14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene;SB1317, >=98%;SB1317(TG-02) hydrochloride;CS-915;TG02; SB 1317; TG 02; SB-1317; TG-02;TG02;TG-02;20-Oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-methyl- | | CAS: | 937270-47-8 | | MF: | C23H24N4O | | MW: | 372.46 | | EINECS: | | | Product Categories: | | | Mol File: | 937270-47-8.mol |  |
| | SB1317 Chemical Properties |
| Boiling point | 575.5±60.0 °C(Predicted) | | density | 1.16±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; ≥44.87 mg/mL in DMSO; ≥3.98 mg/mL in EtOH with gentle warming and ultrasonic | | form | solid | | pka | 8.03±0.20(Predicted) | | color | Off-white to light yellow |
| | SB1317 Usage And Synthesis |
| Uses | TG 02 is a cyclin dependent kinase inhibitors (CDK inhibitors) for the treatment of chronic lymphocytic leukemia. | | in vivo | (E/Z)-Zotiraciclib (50 and 75 mg/kg; p.o. once daily for 3 weeks) inhibits tumor growth[1].?
(E/Z)-Zotiraciclib (15 and 75 mg/kg; p.o. once daily 2 days on and 5 days off; i.p. once daily 5 days on 5 days off) inhibits tumor growth in two manners[1]. | Animal Model: | Male BALB/c mice with HCT-116 colon cancer cells xenografts[1] | | Dosage: | 50 and 75 mg/kg | | Administration: | Oral gavage; 50 and 75 mg/kg once daily for 3 weeks | | Result: | Significantly inhibited the growth of tumors with a mean TGI of 82%.
|
| Animal Model: | Male BALB/c mice with lymphoma Ramos cells xenografts[1] | | Dosage: | 15 and 75 mg/kg | | Administration: | Oral gavage and intraperitoneal injection ; 75 mg/kg once daily 2 days on and 5 days off (p.o.) and 15 mg/kg once daily 5 days on 5 days off (i.p.) | | Result: | Significantly inhibited the growth of tumors with mean TGIs of 42% and 63% for the oral and ip delivery methods, respectively.
|
| | IC 50 | CDK2: 13 nM (IC50); JAK2: 73 nM (IC50); FLT3: 56 nM (IC50) |
| | SB1317 Preparation Products And Raw materials |
|